Miransertib

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameMiransertib
Drug Alias NameARQ-092MK-7075
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitors
TargetsSerine/threonine-protein kinase AKT1
Therapy Area/IndicationsSolid tumoursPIK3CA-Related Overgrowth SpectrumEndometrial Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArqule Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Human Genome Research InstituteMerck Sharp & Dohme LLC
Inactive CompaniesArqule Inc
Active IndicationsProteus SyndromeProteus Infections
Inactive IndicationsSolid tumoursPIK3CA-Related Overgrowth SpectrumEndometrial Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A